Table 1.

Patient and tumor characteristics by Prosigna (PAM50) subtype

	Total study set		Molecular subtype
			Luminal A		Luminal B		Basal-like		Her2-E
Characteristics	N	%	N	%	N	%	N	%	N	%
Number of patients	460	–	161	35	118	27	61	13	120	26
Age
< 40 years	96	21	23	14	26	22	19	31	28	23
40–49 years	233	51	94	58	63	53	25	41	51	43
50–59 years	131	28	44	27	29	25	17	28	41	34
Lymph nodes excised
None	19	4	8	5	7	6	1	2	3	3
1–3	110	24	42	26	27	23	14	23	27	23
4–9	268	58	97	60	67	57	39	64	65	54
> 9	6	14	14	9	17	14	7	11	25	21
Lymph node status
Negative	43	9	16	10	4	3	10	16	13	11
1–3 positive	271	59	106	66	72	61	33	54	60	50
4+ positive	127	28	31	19	35	30	17	28	44	37
Unknown	19	4	8	5	7	6	1	2	3	3
Tumor size
0–20 mm	132	29	60	37	36	31	14	23	22	18
21–50 mm	239	52	77	48	61	52	30	49	71	59
> 50 mm	85	18	24	15	21	18	13	21	27	23
Unknown	4	1	0	0	0	0	4	7	0	0
Deep fascia invasion
Absent	346	75	127	79	93	79	45	74	81	68
Present	109	24	32	20	25	21	15	25	37	31
Unknown	5	1	2	1	0	0	1	2	2	2
Histologic type
Ductal carcinoma	393	85	132	82	99	84	52	85	110	92
Lobular carcinoma	33	7	16	10	13	11	1	2	3	3
Other	28	6	11	7	5	4	6	10	6	5
Unknown	6	1	2	1	1	1	2	3	1	1
Malignancy gradea
Grade I	65	17	46	35	15	15	1	2	3	3
Grade II	242	62	81	61	73	74	22	42	66	60
Grade III	86	22	5	4	11	11	29	56	41	37
HR status
Positive	329	72	146	91	112	95	6	10	65	54
Negative	114	25	6	4	5	4	52	85	51	43
Unknown	17	4	9	6	1	1	3	5	4	3
Systemic treatment
Control or levamisole	113	25	37	23	34	29	10	16	32	27
C or CMF	347	75	124	77	84	71	51	84	88	73
ROR score groups
Low (0–51)	155	34	135	84	2	2	14	23	4	3
Intermediate (52–71)	148	32	26	16	50	42	40	66	32	27
High (72–100)	157	34	0	0	66	56	7	11	84	70

PAM50 prediction analysis of microarray 50, C cyclophosphamide, CMF cyclophosphamide, methotrexate and fluorouracil, HR hormone receptor, Her2-E human epidermal growth factor receptor 2-enriched, ROR risk of recurrence

^aDuctal carcinomas only